This site is intended for
US
Healthcare Professionals only.

For Patients
 

I-O Biomarkers

Click a research area to learn more.

 
Four key I-O biomarkers expressed in a tumor/effector cell diagram
 
 
 
 

Immuno-Oncology
(I-O) biomarkers may be used to advance precision medicine

Bristol-Myers Squibb is committed to investigating four key areas of I-O biomarker research.

Click on one of the biomarker categories to learn more.

Tumor Antigens

Tumor antigens are recognized as nonself or foreign by the host immune system.1 They can initiate the adaptive immune response by priming the immune system.1,2 Several Immuno-Oncology (I-O) biomarkers related to inflamed tumor markers are currently under investigation.

Learn about:

MSI-H/dMMR

Inflamed Tumor Markers

Inflamed tumors show evidence of immune-cell infiltration and activation in the tumor microenvironment.3,4 Several Immuno-Oncology (I-O) biomarkers related to inflamed tumor markers are currently under investigation.

Learn about:

Inflammation Gene
Signature

Immune Suppression Markers

Cells and proteins within the tumor and its microenvironment can suppress T-cell activation, promote T-cell exhaustion, or activate regulatory T-cells.5,6 Several exploratory Immuno-Oncology (I-O) biomarkers are associated with inhibition of the antitumor response.

Learn about:

Host Environment Factors

Many factors in the host envrionment may play a role in modulating an immune response. Outside of the tumor microenvironment, factors such as smoking, diet, UV exposure, infectious agents, and the gut microbiome can favorably or unfavorably affect the antitumor response.7-9

Learn about:

Microbiome
Select a biomarker
  • Tumor Antigens
  • Inflamed Tumor
    Markers
  • Immune Suppression
    Markers
  • Host Environment
    Factors

Immuno-Oncology (I-O) biomarkers may be used to advance precision medicine

Bristol-Myers Squibb is committed to investigating four key areas of I-O biomarker research. Tap on one of the biomarker categories to learn more.

Tumor antigens are recognized as nonself or foreign by the host immune system.1 They can initiate the adaptive immune response by priming the immune system.1,2 Several
Immuno-Oncology (I-O) biomarkers related to tumor antigens are currently under investigation.

Inflamed tumors show evidence of immune-cell infiltration and activation in the tumor microenvironment.3,4 Several Immuno-Oncology (I-O) biomarkers related to inflamed tumor markers are currently under investigation.

Cells and proteins within the tumor and its microenvironment can suppress T-cell activation, promote T-cell exhaustion, or activate regulatory T-cells.5,6 Several exploratory Immuno-Oncology (I-O) biomarkers are associated with inhibition of the antitumor response.

Many factors in the host envrionment may play a role in modulating an immune response. Outside of the tumor microenvironment, factors such as smoking, diet, UV exposure, infectious agents, and the gut microbiome can favorably or unfavorably affect the antitumor response.7-9

Microbiome

Tap the links below to navigate to the individual biomarker pages.

Thumbnail for the I-O Biomarkers: Under Investigation for Their Role in Immuno-Therapy video Thumbnail for the I-O Biomarkers: Under Investigation for Their Role in Immuno-Therapy video

I-O biomarkers: Under investigation for their role in immuno-therapy

Learn more about where our I-O biomarker research is focused

Watch video

Get I-O Resources

Order or download
educational tools for your
patients and practice

See all resources

Clinical Trials

Learn more about our
current clinical trials

Learn more

REFERENCES–Host environment factors

1. Chen DS, Mellman I. Elements of cancer immunity and the cancer-immune set point. Nature. 2017;541(7637):321-330. 2. Alexandrov LB, Nik-Zainal S, Wedge DC, et al. Signatures of mutational processes in human cancer. Nature. 2013;500(7463):415-421. 3. Sharma P, Allison JP. The future of immune checkpoint therapy. Science. 2015;348(6230):56-61. 4. National Cancer Institute. Microbiome. NCI Dictionary of Cancer Terms. www.cancer.gov/publications/
dictionaries/cancer-terms/def/microbiome. Accessed May 10, 2018. 5. Zitvogel L, Galluzzi L, Viaud S, et al. Cancer and the gut microbiota: an unexpected link. Sci Transl Med. 2015. doi10.1126/scitranslmed. 3010473. 6. Routy B, Le Chatelier E, Derosa L, et al. Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors. Science. 2018;359(6371):91-97. 7. Gopalakrishnan V, Spencer CN, Nezi L, et al. Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients. Science. 2018;359(6371):97-103. 8. Kaiser J. Gut microbes shape response to cancer immunotherapy. Science. 2017;358(6363):573. 9. Li Q, Gao Z, Wang H, et al. Intestinal immunomodulatory cells (T lymphocytes): a bridge between gut microbiota and diabetes. Mediators Inflamm. 2018. doi:10.1155/2018/9830939. 10. Ranjan R, Rani A, Metwally A, McGee HS, Perkins DL. Analysis of the microbiome: advantages of whole genome shotgun versus 16S amplicon sequencing. Biochem Biophys Res Commun. 2016;469(4):967–977. 11. Turnbaugh PJ, Ley RE, Hamady M, Fraser-Liggett C, Knight R, Gordon JI. The human microbiome project. Nature. 2007; 449(7164):804-810.